Others here have offered the opinion that "Dropping generics at this time shows they are focused. A new focus. When adva-27a hits, nothing will compete with it so why bother with generics? They originally started generics to fund adva-27a."
In many of my past experiences, when a stock price acts "crazy" and isn't doing the "normal" trading circumstances one would expect, there tends to be something hiding in the shadows. In this case, I don't think its the boogeyman, I think we are heating up for a PR that will astonish most stinky pinky traders. Hold on to those shares folks!
News 
Market Data 
Discover 
